Assay News and Research

RSS

CASdetec: new CRISPR-based SARS-CoV-2 detection platform detects nucleic acids with high sensitivity and specificity

To add to existing CRISPR-based nucleic acid detection protocols, a team of researchers recently established a new SARS-CoV-2 detection protocol based on their previously reported platform - CDetection (Cas12b-mediated DNA detection). They combined nucleic-acid amplification methods and sample treatment protocols with CDetection and established an integrated nucleic acid detection platform called CRISPR-assisted detection or CASdetec. CASdetec has a detection limit of 1×104 copies/mL for SARS-CoV-2 pseudovirus, without any observed cross-reactivity.

26 May 2021

New COVID-19 test can deliver highly accurate results in less than 15 minutes

A new rapid coronavirus test developed by KAUST scientists can deliver highly accurate results in less than 15 minutes.

26 May 2021

Researchers develop a method to detect SARS-CoV-2 and variants simultaneously

Researchers demonstrate a method of detecting the presence and mutations in the SARS-CoV-2 virus using the smaller and cheaper Oxford Nanopore sequencer, a method they believe could make pandemic surveillance faster and cheaper.

26 May 2021

Could GRP78 be a therapeutic target against COVID-19?

A new study by a team of researchers at the Keck School of Medicine, University of Southern California, USA, reports a potentially important therapeutic target in the form of a molecule called GRP78 that promotes the entry and protein production by many viruses. The team's paper has been published in the Journal of Biological Chemistry.

26 May 2021

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

A new study aims to identify antibody-based biomarkers associated with the humoral immune response that could be a standard CoP candidate for COVID-19. Further, standardization of research methods to measure these biomarkers has also been conducted.

25 May 2021

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

New research by a team of scientists in the USA describes the potential utility of a drug called probenecid, commonly used to treat gout, to treat this devastating viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19.

25 May 2021

SARS-CoV-2 UK variant may induce more inflammation, study suggests

Since COVID-19 was first detected in December 2019 in Wuhan, China, many different variants of its causative virus – SARS-CoV-2 – have emerged. Through increased viral fitness, some of these have risen to predominance over earlier variants in a remarkably short period of time. New research, by a team of scientists at major institutions in France, examines the reasons behind this phenomenon in one such variant of concern (VOC), the so-called UK variant.

25 May 2021

Could 6′,6′-difluoro-aristeromycin (DFA) have broad-spectrum antiviral potential against coronaviruses?

Researchers at the Leiden University Medical Center demonstrated that low-micromolar concentrations of 6′,6′-difluoro24 aristeromycin (DFA), an adenosine nucleoside analog, strongly inhibits the replication of Middle East respiratory syndrome coronavirus (MERS-CoV) in a cell-based infection assay.

25 May 2021

Do mixed COVID-19 vaccines provide immunity?

The initial results of the CombivacS trial found that the antibody levels in individuals increased by 150 times when the Pfizer messenger ribonucleic acid (mRNA) vaccine was given after a first dose of the AstraZeneca severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, with only mild common side effects.

24 May 2021

Researchers take steps to standardize correlates of protection against SARS-CoV-2

Antibodies, Antibody, Assay, Coronavirus, Efficacy, Healthcare, Pandemic, Protein, Receptor, Research, Vaccine, Virus, Coronavirus Disease COVID-19,

24 May 2021

Memory B cells with a functional anti-SARS-CoV-2 response persist despite loss of specific IgG

In Munich, Germany, scientists at Ludwig Maximilian University studied temporal adaptive immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to better understand protection against re-infection. They found functional properties of persisting memory B specific to SARS-CoV-2 may help in protect against the virus.

23 May 2021

Researchers uncover differences in itch mechanisms

Chronic skin itching drives more people to the dermatologist than any other condition. In fact, the latest science literature finds that 7% of U.S. adults, and between 10 and 20% of people in developed countries, suffer from dermatitis, a common skin inflammatory condition that causes itching.

21 May 2021

Canopy Biosciences develops spatial proteomics assay for COVID-19

Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19.

From Bruker Nano Surfaces and Metrology 21 May 2021

Pfizer-BioNTech and Sinovac vaccines boost SARS-CoV-2 neutralizing responses

Researchers in the United States and Chile have provided preliminary evidence that individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – mount a robust neutralizing antibody response against the virus that can be significantly boosted by two doses of Sinovac Biotech’s CoronaVac vaccine or one dose of Pfizer-BioNTech’s BNT162b2 vaccine.

21 May 2021

Spike antibodies after vaccination with Pfizer and Oxford vaccines

A preprint discusses the results of a study of antibody responses to the first and second dose of currently available SARS-CoV-2 vaccines, Pfizer and Oxford.

19 May 2021

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

A new study has been published on the medRxiv* preprint server which focuses on validating the serological assays using a large cohort of healthcare workers.

19 May 2021

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

In a new study posted to the bioRxiv* preprint server, researchers from the United States report that two iminosugar glucosidase inhibitors have the ability to suppress the replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in tissue culture – at concentrations of at least 100 times lower than required for cytotoxic effects.

19 May 2021

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Researchers in the United States have provided the first evidence that messenger RNA (mRNA)-based vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2) induce a broader array of antibody subtypes against the viral spike protein than natural infection does.

19 May 2021

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

In a new study, researchers used an antibody discovery technology to identify a new potently neutralizing antibody with a unique mode of SARS-CoV-2 recognition. They reported their results on the bioRxiv preprint server.

18 May 2021

New COVID-19 testing technology is a cheaper, faster alternative to tube-based RT-PCR tests

Throughout the COVID-19 pandemic, supply chain shortages of reagents and test kits have limited the rapid expansion of clinical testing needed to contain the virus.

18 May 2021

Assay News and Research

CASdetec: new CRISPR-based SARS-CoV-2 detection platform detects nucleic acids with high sensitivity and specificity

New COVID-19 test can deliver highly accurate results in less than 15 minutes

Researchers develop a method to detect SARS-CoV-2 and variants simultaneously

Could GRP78 be a therapeutic target against COVID-19?

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

SARS-CoV-2 UK variant may induce more inflammation, study suggests

Could 6′,6′-difluoro-aristeromycin (DFA) have broad-spectrum antiviral potential against coronaviruses?

Do mixed COVID-19 vaccines provide immunity?

Researchers take steps to standardize correlates of protection against SARS-CoV-2

Memory B cells with a functional anti-SARS-CoV-2 response persist despite loss of specific IgG

Researchers uncover differences in itch mechanisms

Canopy Biosciences develops spatial proteomics assay for COVID-19

Pfizer-BioNTech and Sinovac vaccines boost SARS-CoV-2 neutralizing responses

Spike antibodies after vaccination with Pfizer and Oxford vaccines

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

New COVID-19 testing technology is a cheaper, faster alternative to tube-based RT-PCR tests

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News